Neurologic clinical trial - Ivy Brain Tumor Center: 2020-08

Status:

Open

ClinicalTrials.gov:

NCT04424966

A Phase 0 Study of Infigratinib in Recurrent High-Grade Glioma Participants Scheduled for Resection to Evaluate Central Nervous System (CNS) Penetration With PK Triggered Expansion Cohort

Drug

Infigratinib

Phase

Phase 0

Condition

Glioblastoma Glioma

Keywords

Ivy Brain Tumor Center | Infigratinib